Open an account

Cartesian Therapeutics

RNAC · NASDAQ

$6.40+$0.315 (+5.18%)TodayMarket closed ·
Prev close $6.08

About RNAC

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in mRNA cell therapies for the treatment of autoimmune diseases. The company is headquartered in Frederick, Maryland and currently employs 75 full-time employees. The company went IPO on 2016-06-22. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.

Employees
75
Headquarters
Frederick, Maryland
Listed
Jun 22, 2016
Sector
Health Care
Industry
Biotechnology
Website
cartesiantherapeutics.com

RNAC key statistics

Market cap
193.48M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
155.95K
Volume
168.59K
Open price
$6.09
High today
$6.53
Low today
$6.07
52 Week high
$11.00
52 Week low
$5.60

Cartesian Therapeutics (RNAC) at a glance

As of Oct 20, 2026, Cartesian Therapeutics (RNAC) shares are priced at $6.40, giving the company a market cap of 193.48M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.07 and $6.53. The current price is 5.3% above the day's low and 2.0% below its high.

Volume so far is 168.59K shares, in line with the average of 155.95K shares a day.

Over the past year Cartesian Therapeutics has ranged from $5.60 to $11.00, and now sits 15% of the way up that range.

Cartesian Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $0.61 per share against an estimate of -$0.8859.

The average analyst price target is $34.34, 437.0% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $34.34
Low
$16.16
Now
$6.40
High
$46.20

RNAC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 90.6% on average.

  1. Q3 FY24: reported -$1.13 per share against an estimate of -$0.9282
  2. Q4 FY24: reported -$0.59 per share against an estimate of -$0.816
  3. Q1 FY25: reported -$0.68 per share against an estimate of -$0.7198
  4. Q2 FY25: reported $0.50 per share against an estimate of -$0.8262
  5. Q3 FY25: reported -$1.38 per share against an estimate of -$0.8619
  6. Q4 FY25: reported -$3.57 per share against an estimate of -$0.8704
  7. Q1 FY26: reported -$1.46 per share against an estimate of -$0.901
  8. Q2 FY26: reported $0.61 per share against an estimate of -$0.8859

RNAC news

  • Vandana Singh

    New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market

  • Press releaseGlobe Newswire

    Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

  • Vandana Singh

    Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment

  • Vandana Singh

    Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus

  • Vandana Singh

    AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate

  • Rishabh Mishra

    US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert

  • Vandana Singh

    Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients

  • Press releaseGlobe Newswire

    Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Similar companies

Companies in the same industry as Cartesian Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.